Lenalidomide and its role in the management of multiple myeloma

Patrizia Falco, Federica Cavallo, Alessandra Larocca, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticle

Abstract

Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.

Original languageEnglish
Pages (from-to)865-874
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume8
Issue number6
DOIs
Publication statusPublished - 2008

Fingerprint

Multiple Myeloma
Thalidomide
Biological Factors
Therapeutics
Drug Resistance
Dexamethasone
Parents
lenalidomide
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • Lenalidomide
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008). Lenalidomide and its role in the management of multiple myeloma. Expert Review of Anticancer Therapy, 8(6), 865-874. https://doi.org/10.1586/14737140.8.6.865

Lenalidomide and its role in the management of multiple myeloma. / Falco, Patrizia; Cavallo, Federica; Larocca, Alessandra; Liberati, Anna Marina; Musto, Pellegrino; Boccadoro, Mario; Palumbo, Antonio.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 6, 2008, p. 865-874.

Research output: Contribution to journalArticle

Falco, P, Cavallo, F, Larocca, A, Liberati, AM, Musto, P, Boccadoro, M & Palumbo, A 2008, 'Lenalidomide and its role in the management of multiple myeloma', Expert Review of Anticancer Therapy, vol. 8, no. 6, pp. 865-874. https://doi.org/10.1586/14737140.8.6.865
Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M et al. Lenalidomide and its role in the management of multiple myeloma. Expert Review of Anticancer Therapy. 2008;8(6):865-874. https://doi.org/10.1586/14737140.8.6.865
Falco, Patrizia ; Cavallo, Federica ; Larocca, Alessandra ; Liberati, Anna Marina ; Musto, Pellegrino ; Boccadoro, Mario ; Palumbo, Antonio. / Lenalidomide and its role in the management of multiple myeloma. In: Expert Review of Anticancer Therapy. 2008 ; Vol. 8, No. 6. pp. 865-874.
@article{d437f567672d4a7587d21c98808ebe6d,
title = "Lenalidomide and its role in the management of multiple myeloma",
abstract = "Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.",
keywords = "Combination therapy, Lenalidomide, Multiple myeloma",
author = "Patrizia Falco and Federica Cavallo and Alessandra Larocca and Liberati, {Anna Marina} and Pellegrino Musto and Mario Boccadoro and Antonio Palumbo",
year = "2008",
doi = "10.1586/14737140.8.6.865",
language = "English",
volume = "8",
pages = "865--874",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Lenalidomide and its role in the management of multiple myeloma

AU - Falco, Patrizia

AU - Cavallo, Federica

AU - Larocca, Alessandra

AU - Liberati, Anna Marina

AU - Musto, Pellegrino

AU - Boccadoro, Mario

AU - Palumbo, Antonio

PY - 2008

Y1 - 2008

N2 - Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.

AB - Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.

KW - Combination therapy

KW - Lenalidomide

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=47249145259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249145259&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.6.865

DO - 10.1586/14737140.8.6.865

M3 - Article

C2 - 18533796

AN - SCOPUS:47249145259

VL - 8

SP - 865

EP - 874

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 6

ER -